▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Todd Campbell

tmfebcapital

@ebcapital

Todd has been helping buy side portfolio managers as an independent researcher for over a decade. In 2003, Todd founded E.B. Capital Markets, LLC, a research firm providing action oriented ideas to professional investors. Todd has provided insight to a variety of publications, including SmartMoney, Barron's, and CNN/fn.

Recent Articles by Todd Campbell

Mar 21, 2014 by Todd Campbell

Here's How Amgen May Help Merck

Studies using Amgen's (AMGN) PCSK9 drug Evolocumab (AMG-145) alongside Merck's (MRK) Zetia could boost Zetia sales.

Mar 21, 2014 by Todd Campbell

Medivation, Inc: Fast Growing Drugs That May Become Blockbusters

Medivation (MDVN) may see sales of its prostate cancer drug Xtandi hit a blockbuster run rate this year.

Mar 20, 2014 by Todd Campbell

Do You Take Statins? If Not, You May Be Soon

A change in guidelines for prescribing statins could boost sales for Merck (MRK) and AstraZeneca (AZN), and may someday increase demand for PCSK9 drugs from Regeneron (REGN), Amgen (AMGN), and Pfizer (PFE).

Mar 20, 2014 by Todd Campbell

Here's What You Need to Know About Castlight Health, Inc.

Castlight (CSLT) stellar IPO sets the bar for perfection, ignoring risks from major insurers United Healthcare (UNH), WellPoint (WLP), and Cigna (CI).

Mar 19, 2014 by Todd Campbell

Shorts Piling on to Myriad Genetics: Time to Panic?

Myriad's (MYGN) investors may want to reconsider doubts stemming from the company losing its monopoly on tests for BRCA gene mutations.

Mar 19, 2014 by Todd Campbell

1 More Promising Asthma Drug by GlaxoSmithKline

GlaxoSmithKline's (GSK) mepolizumab posted solid phase 3 results for severe asthma, potentially strengthening its lead over Astrazeneca (AZN) and Merck (MRK).

Mar 19, 2014 by Todd Campbell

2 Ferns Controversy = Obamacare Success?

United Healthcare (UNH) and Aetna (AET) may benefit from the administration's push to sign up millennials.

Mar 19, 2014 by Todd Campbell

Why Pfizer Investors Should Watch Quark This Summer

A read out on a mid stage trial this summer may offer clues as to whether Pfizer (PFE) may someday have a competitor to Novartis (NVS) and Regeneron (REGN)

Mar 18, 2014 by Todd Campbell

Is a Bubble Building in Large-Cap Biotechs?

Big cap biotechs Celgene (CELG), Biogen (BIIB), and Amgen (AMGN) have posted impressive gains in the past year that have all three trading at their highest valuation in years.

Mar 17, 2014 by Todd Campbell

Should You Believe Tesaro's Hype?

A new license for promising technology from AnaptysBio could eventually help increase the number of drugs in Tesaro's (TSRO) pipeline.

Mar 16, 2014 by Todd Campbell

3 Top Selling Drugs Investors Ought to Know About

Biogen (BIIB), Johnson & Johnson (JNJ) and Amgen (AMGN) all have fast growing drugs about to become blockbusters this year.

Mar 14, 2014 by Todd Campbell

It's Official: Merck Now Owns Part of Alnylam

Alnylam (ALNY) has completed its acquisition of Merck's (MRK) RNAi business, handing over a 3% ownership stake in the company.

Mar 13, 2014 by Todd Campbell

3 Health Care Companies Warren Buffett Loves

Here's why DaVita (DVA), Johnson & Johnson (JNJ), and Sanofi (SNY) are part of Berkshire's holdings.

Mar 13, 2014 by Todd Campbell

With FDA Concerns Public, What's Next for These Cholesterol Drugs?

The FDA wants Regeneron (REGN), Amgen (AMGN) and Pfizer (PFE) to more closely look at their promising cholesterol fighting drugs. That could mean delays, but may not be a deathknell.

Mar 12, 2014 by Todd Campbell

Can Gilead Dominate The HIV Drug Market Again in 2014?

Gilead (GILD) has a robust lineup of HIV drugs that remain the market share leaders.

Mar 12, 2014 by Todd Campbell

Here's What Health Insurers Have in Common With Grocers

United Healthcare, WellPoint, and Aetna operate in a low margin industry increasingly reliant on volume for profit growth.

Mar 10, 2014 by Todd Campbell

Who Will Capture This $3.5 Billion Opportunity?

Thanks to a promising late stage drug, Ophthotech may have a shot at challenging Regeneron (REGN) Eylea and Novartis' (NVS) Lucentis one day.

Mar 10, 2014 by Todd Campbell

What You Need to Know About Sangamo Biosciences' Surge

Sangamo's (SGMO) HIV drug SB-728-T may offer a new way of battling the disease that may allow it to compete against Johnson & Johnson (JNJ) and Gilead (GILD).

Mar 9, 2014 by Todd Campbell

Lilly Underwhelms Investors Again

The FDA has opted against Lilly's (LLY) empagliflozin, dealing another blow to the struggling drug giant.

Mar 7, 2014 by Todd Campbell

2 Things You Should Know About Insurers in 2014

Big insurers like United Healthcare (UNH), WellPoint (WLP), and Aetna (AET) face big changes this year; here are 2 things investors should watch in 2014.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services